I'm not only excited about upcoming phase 2 data, but also the potential for the TolloTest. From my understanding, this test will measure for presence of the 3CL protease which is created in large numbers by the virus immediately after infection, at 70 times the number of viral protein chains, so it's likely the best early indicator of infection. These virus-produced enzymes should be detectable even earlier than the virus itself via the PCR method.
Getting this detection method approved and in a format that allows rapid testing will be a game changer. PCR testing, while highly accurate, takes too long for screening at events, family gatherings, and when used for travel leaves the window open for infections occurring in the window between testing and travel. Quick tests that measure antibodies are useless as a person can be infected and transmissible for days or a week before the antibodies show up to be detected. The 3CL protease suppresses the body's initial immune response to allow time for the virus to rapidly spread. A quick test for 3CL protease presence at the initial stages of infection would be the Holy Grail of testing and greatly limit spread of the virus.
Gerald hinted at this being a quick test in the recent investor conference call, I believe. If they're able to perfect the technology and package it in a kit that can be used in schools, prior to events, at home, etc., that changes the dynamics of the pandemic and we start managing treatments with antivirals like Tollovir and Paxlovid instead of advocating more and more boosters.
I'm thinking the last tweet I posted from 12/20/21 might be related to the TolloTest.
AI
Market Data 
Markets 
